Abstract
Vosoritide is an analogue of C-type natriuretic peptide (CNP), a potent stimulator of endochondral bone growth. Like any growth agent used in children, efficacy as indicated by annualized growth velocity (AGV) should be evaluated in the context of pubertal milestone timing. We report on the growth velocity during puberty and pubertal milestones in children with achondroplasia (ACH) treated with vosoritide.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
